# US 5,350,575 A · IBDV VP2 epitope recognized by virus neutralizing and protective monoclonal antibodies > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 5,350,575 A - Document ID: US5350575A - Status: Granted - Kind: A - Application number: 08/052,289 - Filed: 1993-04-26 - Granted: 1994-09-27 - Earliest claimed: 1987-06-26 - Assignees: Commonwealth Scientific and Industrial Research Organization - Inventors: Ahmed A. Azad; Mittur N. Jagadish; Kevin J. Fahey - Web page: https://patentgrep.com/patent/US5350575A ## CPC - C07K 14/005: from viruses - C07K 16/10: RNA viruses - A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53) - C12N 2720/10022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) ## Abstract A recombinant DNA molecule comprising a nucleotide sequence coding for a conformational epitope of the VP2 polypeptide of IBDV. In particular, a DNA molecule comprising a sequence which substantially corresponds to the AccI-SpeI fragment, and optionally the ScaI-XhoI fragment, of the IBDV genome segment coding for the VP2 polypeptide. Synthetic peptides or polypeptides, including fused polypeptides, prepared by expression of host cells containing these DNA molecules are also disclosed, as well as compositions for stimulating an immune response against IBDV comprising at least one such synthetic peptide or polypeptides. ## Claims ### Claim 1 A recombinant DNA molecule consisting essentially of a nucleotide sequence coding for a non-full length fragment of VP2 polypeptide of IBDV including a conformational epitope of the VP2 polypeptide, said conformational epitope encoded by the AccI-SpeI fragment, optionally together with the ScaI-XhoI fragment, of the IBDV genome segment coding for the VP2 polypeptide. ### Claim 2 (depends on 1) A recombinant DNA molecule according to claim 1, wherein said nucleotide sequence is operatively linked to an expression control sequence. ### Claim 3 (depends on 1) A recombinant DNA cloning vehicle or vector capable of expressing a non-full length fragment of the VP2 polypeptide of IBDV including a conformational epitope of the VP2 polypeptide, said cloning vehicle or vector having inserted therein a nucleotide sequence according to claim 1, said sequence being operatively linked to an expression control sequence. ### Claim 4 (depends on 2) A host cell containing a recombinant DNA molecule according to claim 2. ### Claim 5 (depends on 3) A host cell containing a recombinant DNA cloning vehicle or vector according to claim 3. ### Claim 6 A synthetic peptide or polypeptide having the antigenicity of a non-full length fragment of the VP2 polypeptide of IBDV including a conformational epitope of the VP2 polypeptide, said conformational epitope encoded by the AccI-SpeI fragment, optionally together with the ScaI-XhoI fragment, of the IBDV genome segment coding for the VP2 polypeptide. ### Claim 7 A fused polypeptide comprising a polypeptide having the antigenicity of a non-full length fragment of the VP2 polypeptide of IBDV including a conformational epitope of the VP2 polypeptide, said conformational epitope encoded by the AccI-SpeI fragment, optionally together with the ScaI-XhoI fragment, of the IBDV genome segment coding for the VP2 polypeptide as the C-terminal sequence, and an additional non-IBDV polypeptide encoded by an expression vehicle or vector as the N-terminal sequence fused thereto. ### Claim 8 (depends on 4) A method of preparing a synthetic peptide or polypeptide having the antigenicity of a non-full length fragment of the VP2 polypeptide of IBDV including a conformational epitope of the VP2 polypeptide, said conformational epitope encoded by the AccI-SpeI fragment, optionally together with the ScaI-XhoI fragment, of the IBDV genome segment coding for the VP2 polypeptide, which comprises expression of a host cell according to claim 4, and recovery of the synthetic peptide or polypeptide or fused polypeptide. ### Claim 9 (depends on 5) A method of preparing a synthetic peptide or polypeptide having the antigenicity of a non-full length fragment of the VP2 polypeptide of IBDV including a conformational epitope of the VP2 polypeptide, said conformational epitope encoded by the AccI-SpeI fragment, optionally together with the ScaI-XhoI fragment, of the IBDV genome segment coding for the VP2 polypeptide, which comprises expression of a host cell according to claim 5, and recovery of the synthetic peptide or polypeptide or fused polypeptide. ### Claim 10 (depends on 4) A method of preparing a fused polypeptide comprising a polypeptide having the antigenicity of a non-full length fragment of the VP2 polypeptide of IBDV including a conformational epitope of the VP2 polypeptide, said conformational epitope encoded by the AccI-SpeI fragment, optionally together with the ScaI-XhoI fragment, of the IBDV genome segment coding for the VP2 polypeptide as the C-terminal sequence, and an additional non-IBDV polypeptide encoded by an expression vehicle or vector as the N-terminal sequence fused thereto, which comprises expression of a host cell according to claim 4, and recovery of the synthetic peptide or polypeptide or fused polypeptide. ### Claim 11 (depends on 5) A method of preparing a fused polypeptide comprising a polypeptide having the antigenicity of a non-full length fragment of the VP2 polypeptide of IBDV including a conformational epitope of the VP2 polypeptide, said conformational epitope encoded by the AccI-SpeI fragment, optionally together with the ScaI-XhoI fragment, of the IBDV genome segment coding for the VP2 polypeptide as the C-terminal sequence, and an additional non-IBDV polypeptide encoded by an expression vehicle or vector as the N-terminal sequence fused thereto, which comprises expression of a host cell according to claim 5, and recovery of the synthetic peptide or polypeptide or fused polypeptide. ### Claim 12 A composition for stimulating an immune response against IBDV, which comprises at least one synthetic peptide or polypeptide having the antigenicity of a non-full length fragment of the VP2 polypeptide of IBDV including a conformational epitope of the VP2 polypeptide, said conformational epitope encoded by the AccI-SpeI fragment, optionally together with the ScaI-XhoI fragment, of the IBDV genome segment coding for the VP2 polypeptide, together with a pharmaceutically acceptable carrier therefor. ### Claim 13 (depends on 12) A composition according to claim 12 which further comprises an adjuvant. ### Claim 14 A composition for stimulating an immune response against IBDV, which comprises a fused polypeptide comprising a polypeptide having the antigenicity of a non-full length fragment of the VP2 polypeptide of IBDV including a conformational epitope of the VP2 polypeptide, said conformational epitope encoded by the AccI-SpeI fragment, optionally together with the ScaI-XhoI fragment of the IBDV genome segment coding for the VP2 polypeptide as the C-terminal sequence, and an additional non-IBDV polypeptide encoded by an expression vehicle or vector as the N-terminal sequence fused thereto, together with a pharmaceutically acceptable carrier therefor. ### Claim 15 (depends on 14) A composition according to claim 14, further comprising an adjuvant. ### Claim 16 (depends on 12) A method of stimulating an immune response against IBDV in poultry, which comprises administering to said poultry a composition according to claim 12. ### Claim 17 (depends on 14) A method of stimulating an immune response against IBDV in poultry, which comprises administering to said poultry a composition according to claim 14.